Lifyorli relacorilant Updated Nov 5
The next major catalyst is the December 17, 2026 PDUFA decision on relacorilant's NDA resubmission for Cushing's syndrome. An approval would open a large endocrinology market (currently served by Korlym, which generated ~$498M in the first nine months of 2026) and could significantly expand the drug's total addressable market beyond the already-approved ovarian cancer indication. A second CRL would be a major setback for the Cushing's franchise.
- Lifyorli is the first and only FDA-approved selective glucocorticoid receptor antagonist (SGRA), a novel mechanism that enhances chemotherapy sensitivity by blocking cortisol signaling in tumor cells.
- The drug's commercial launch is accelerating rapidly: Q3 2026 Lifyorli revenue was $91.4 million, up 92% from $47.6 million in Q2 2026, with total company revenue of $340.5 million beating analyst estimates.
- The pivotal ROSELLA Phase 3 trial showed a 35% reduction in risk of death, and the regimen was added to NCCN Guidelines as a preferred treatment option.
- The FDA issued a Complete Response Letter (CRL) for relacorilant in Cushing's syndrome in December 2025, and the resubmission may face similar concerns about the GRACE trial data or liver safety signals.
- Insiders have been selling substantial amounts of stock in October and November 2026, with multiple executives exercising options and selling shares at prices between $80-$116.
- The stock has fallen sharply from its 52-week high of $126.38 to $71.63, a decline of over 43%, suggesting significant de-risking or concerns about the Cushing's PDUFA outcome.